InsiderTrades.com logo
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing   |   Ad
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Laurence Reid net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Laurence Reid Biography and Net Worth

Insider of Decibel Therapeutics
Laurence joined Decibel in January 2020. He previously served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug discovery and development opportunities. Before that, Laurence was CEO of Warp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products, until its merger with Revolution Medicines in 2018. Prior to that, he was the senior vice president and chief business officer of Alnylam Pharmaceuticals, where he was responsible for the company’s business development, finance and legal functions. Before coming to Alnylam, Laurence was the chief business officer at Ensemble Discovery, where he led the company’s strategic planning and corporate development efforts. Laurence previously spent ten years at Millennium Pharmaceuticals in a range of general management and business development positions. In addition to his professional interests, Laurence is a board member of the Possible Project and board advisor to Life Science Cares. He earned his Ph.D. from King’s College London and his B.A. from Cambridge University.

What is Laurence Reid's net worth?

The estimated net worth of Laurence Reid is at least $126,918.59 as of September 15th, 2021. Dr. Reid owns 25,849 shares of Decibel Therapeutics stock worth more than $126,919 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Reid may own. Additionally, Dr. Reid receives a salary of $742,980.00 as Insider at Decibel Therapeutics. Learn More about Laurence Reid's net worth.

How old is Laurence Reid?

Dr. Reid is currently 59 years old. There are 4 older executives and no younger executives at Decibel Therapeutics. Learn More on Laurence Reid's age.

What is Laurence Reid's salary?

As the Insider of Decibel Therapeutics, Inc., Dr. Reid earns $742,980.00 per year. Learn More on Laurence Reid's salary.

How do I contact Laurence Reid?

The corporate mailing address for Dr. Reid and other Decibel Therapeutics executives is 1325 Boylston Street Suite 500, Boston MA, 02215. Decibel Therapeutics can also be reached via phone at 617-370-8701 and via email at [email protected]. Learn More on Laurence Reid's contact information.

Has Laurence Reid been buying or selling shares of Decibel Therapeutics?

Laurence Reid has not been actively trading shares of Decibel Therapeutics during the past quarter. Most recently, on Wednesday, September 15th, Laurence Reid bought 10,000 shares of Decibel Therapeutics stock. The stock was acquired at an average cost of $7.64 per share, with a total value of $76,400.00. Following the completion of the transaction, the insider now directly owns 25,849 shares of the company's stock, valued at $197,486.36. Learn More on Laurence Reid's trading history.

Who are Decibel Therapeutics' active insiders?

Decibel Therapeutics' insider roster includes Laurence Reid (Insider), and Anna Trask (Insider). Learn More on Decibel Therapeutics' active insiders.

Laurence Reid Insider Trading History at Decibel Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Buy10,000$7.64$76,400.0025,849View SEC Filing Icon  
See Full Table

Laurence Reid Buying and Selling Activity at Decibel Therapeutics

This chart shows Laurence Reid's buying and selling at Decibel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Decibel Therapeutics Company Overview

Decibel Therapeutics logo
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Read More

Today's Range

Now: $4.91
Low: $4.90
High: $5.11

50 Day Range

MA: $5.00
Low: $4.91
High: $5.23

2 Week Range

Now: $4.91
Low: $1.61
High: $5.40

Volume

1,261,100 shs

Average Volume

122,002 shs

Market Capitalization

$123.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing   |   Ad
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him